ERBB2 and gastric cancer: Usually, when human epidermal growth factor receptor 2 (HER2) is positive, clinical guidelines recommend that patients with advanced gastric cancer receive targeted therapy (trastuzumab combined with chemotherapy), and for HER2‐negative gastric cancer patients, chemotherapy and immunotherapy are recommended.5